These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Molecular biology of prions causing infectious and genetic encephalopathies of humans as well as scrapie of sheep and BSE of cattle. Prusiner SB Dev Biol Stand; 1991; 75():55-74. PubMed ID: 1686599 [TBL] [Abstract][Full Text] [Related]
25. A survey and a molecular dynamics study on the (central) hydrophobic region of prion proteins. Zhang J; Wang F Curr Pharm Biotechnol; 2014; 15(11):1026-48. PubMed ID: 25373387 [TBL] [Abstract][Full Text] [Related]
26. Prion diseases and emerging prion diseases. Yokoyama T; Mohri S Curr Med Chem; 2008; 15(9):912-6. PubMed ID: 18473798 [TBL] [Abstract][Full Text] [Related]
27. Novel aspects of prions, their receptor molecules, and innovative approaches for TSE therapy. Vana K; Zuber C; Nikles D; Weiss S Cell Mol Neurobiol; 2007 Feb; 27(1):107-28. PubMed ID: 17151946 [TBL] [Abstract][Full Text] [Related]
28. Characterisation of new monoclonal antibodies reacting with prions from both human and animal brain tissues. Cordes H; Bergström AL; Ohm J; Laursen H; Heegaard PM J Immunol Methods; 2008 Sep; 337(2):106-20. PubMed ID: 18657541 [TBL] [Abstract][Full Text] [Related]
29. Prion protein self-interaction in prion disease therapy approaches. Rigter A; Priem J; Langeveld JP; Bossers A Vet Q; 2011 Sep; 31(3):115-28. PubMed ID: 22029882 [TBL] [Abstract][Full Text] [Related]
31. Prion diseases: current understanding of epidemiology and pathogenesis, and therapeutic advances. Caramelli M; Ru G; Acutis P; Forloni G CNS Drugs; 2006; 20(1):15-28. PubMed ID: 16396521 [TBL] [Abstract][Full Text] [Related]
32. Stability properties of PrP(Sc) from cattle with experimental transmissible spongiform encephalopathies: use of a rapid whole homogenate, protease-free assay. Vrentas CE; Greenlee JJ; Baron T; Caramelli M; Czub S; Nicholson EM BMC Vet Res; 2013 Aug; 9():167. PubMed ID: 23945217 [TBL] [Abstract][Full Text] [Related]
33. [Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Part II]. Zaborowski A Psychiatr Pol; 2004; 38(2):297-309. PubMed ID: 15307294 [TBL] [Abstract][Full Text] [Related]
34. [Acquired human prion diseases--past and present issues]. Hagiwara K; Yamakawa Y; Hanada K Uirusu; 2009 Dec; 59(2):155-65. PubMed ID: 20218324 [TBL] [Abstract][Full Text] [Related]
35. Recombinant human prion protein fragment 90-231, a useful model to study prion neurotoxicity. Corsaro A; Thellung S; Villa V; Nizzari M; Aceto A; Florio T OMICS; 2012; 16(1-2):50-9. PubMed ID: 22321015 [TBL] [Abstract][Full Text] [Related]
36. A simple in vitro assay for assessing the efficacy, mechanisms and kinetics of anti-prion fibril compounds. Ladner-Keay CL; Ross L; Perez-Pineiro R; Zhang L; Bjorndahl TC; Cashman N; Wishart DS Prion; 2018; 12(5-6):280-300. PubMed ID: 30223704 [TBL] [Abstract][Full Text] [Related]
37. [A trend of molecular genetics on prion diseases and prion protein]. Muramatsu Y; Shinagawa M Nihon Rinsho; 1993 Sep; 51(9):2494-502. PubMed ID: 8411733 [TBL] [Abstract][Full Text] [Related]